Key result
In patients receiving CD19-directed CAR-T therapy, major adverse cardiac events were uncommon, with an incidence of 4.5% over a median follow-up of 1.3 years.
Answers are grounded in this paper and cite their sources.
This editorial highlights that contemporary CD19-directed CAR-T therapy is associated with a low rate of major adverse cardiac events (4.5%), supporting the use of systematic echocardiographic surveillance during therapy.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Blue et al. (2023) conducted an editorial in Hematologic malignancies undergoing CAR-T therapy (n=44). CD19-directed CAR-T therapy was evaluated on Incidence of major adverse cardiac events (MACE), defined as symptomatic heart failure, nonfatal acute coronary syndrome, nonfatal ischemic stroke, new onset arrhythmia, and cardiac death. In patients receiving CD19-directed CAR-T therapy, major adverse cardiac events were uncommon, with an incidence of 4.5% over a median follow-up of 1.3 years.
Synapse has enriched 10 related papers. Consider them for comparative context: